Audrey’s Life Science Meeting Picks for March 2010 (March 6th Edition) ********************************************************************* Biotech Bay Career Fair, Tuesday Afternoon, March 9, 2010 Event: Biotech Bay Career Fair Location: South San Francisco Conference Center Date and Time: Tuesday, March 9, 2010, 2pm to 7pm Register now at: http://www.biospace.com/jobs/seekersignin.aspx Event Description Looking for a new job? Networking with industry peers in an ever-changing work environment? Sectors include: Biotech * Pharmaceutical * Medical Device & Diagnostics Job seekers can spend a day with HR representatives and Hiring Managers from top biotech, pharma, medical device and diagnostics companies in the Bay area. Who should attend? Candidates with a 4-year degree in the life sciences and a minimum of 2- years of industry related experience are invited to attend. Just register by clicking the button below. (Equivalent work experience may be considered in lieu of a four-year college degree. PhD and Postdoc candidates welcome.) What types of positions are available? Exhibiting companies are recruiting for positions in areas such as: QA/QC, clinical research, engineering, manufacturing, biostatistics, clinical data management, chemistry, regulatory affairs, and research. What companies will be there? Take the time to research what each company is recruiting for to see if you are a match. Most companies will be from the Bay area, but some will travel from other regions to attract top talent! If you can’t make it on event day, you can still pre-register online to allow exhibiting companies to view your resume and contact you outside of the career fair. ********************************************************************** BayBio Medical Device Breakfast, Tuesday, March 9, 2010 Cancelled 1 6/6/2022
Transcript
Audrey’s Life Science Meeting Picks for March 2010(March 6th Edition)
Biotech Bay Career Fair, Tuesday Afternoon, March 9, 2010
Event: Biotech Bay Career FairLocation: South San Francisco Conference CenterDate and Time: Tuesday, March 9, 2010, 2pm to 7pmRegister now at:http://www.biospace.com/jobs/seekersignin.aspx
Event DescriptionLooking for a new job? Networking with industry peers in an ever-changing work environment?Sectors include: Biotech * Pharmaceutical * Medical Device & DiagnosticsJob seekers can spend a day with HR representatives and Hiring Managers from top biotech, pharma, medical device and diagnostics companies in the Bay area.
Who should attend? Candidates with a 4-year degree in the life sciences and a minimum of 2-years of industry related experience are invited to attend. Just register by clicking the button below.(Equivalent work experience may be considered in lieu of a four-year college degree. PhD and Postdoc candidates welcome.)
What types of positions are available? Exhibiting companies are recruiting for positions in areas such as: QA/QC, clinical research, engineering, manufacturing, biostatistics, clinical data management, chemistry, regulatory affairs, and research.
What companies will be there?
Take the time to research what each company is recruiting for to see if you are a match. Most companies will be from the Bay area, but some will travel from other regions to attract top talent! If you can’t make it on event day, you can still pre-register online to allow exhibiting companies to view your resume and contact you outside of the career fair.**********************************************************************
BayBio Medical Device Breakfast, Tuesday, March 9, 2010 Cancelled
Free Recap Webinar, Tuesday Morning, March 9, 2010
Topic: “Value Creation and Sharing Among Universities, Biotechnology, and Commercialization Partners”Date and Time: March 9, 2010, 10:00-11:00 AM Pacific / 1:00-2:00 PM Eastern
1 4/7/2023
Register to attend today!
Join Us
Register for Recap’s free, live webinar on March 9th. Learn how the economic terms of university and other upstream licenses have impacted downstream development and commercialization alliances. We’ll explore:
How upstream licenses have evolved in anticipation of downstream development and commercialization alliances
Allocation of upstream obligations in commercialization alliances
Sharing of commercial outcomes involving multiple layers of licenses
Who should attend:
Biopharma corporate executives
VCs and investment banks
Business development
CFOs and financial executives
Legal
Register to attend today! At http://www.recap.com/882575E5007F1AA1/WebinarInvite?OpenForm
Topic: “From Academia to Entrepreneurship to a Fortune 20 Company – One Person’s Journey” Speaker: Dr. Mike Cunningham, Vice President & General Manager, GPO & Information Services, McKessonDate and Time: 3/09/2010, 6:00 pm Location: TIPS, 1000 Elwell Ct., Palo Alto, CA Cost: $6 - Students/In-transition - Members only $11 - Early-bird Registration - Members only $20 - Late Registration and Non-Members $25 - Walk-ins Register online at www.bio2devicegroup.org
Topic DescriptionMike will share his professional experiences over the last 25+ in diverse employment settings ranging from Academia (UCSF) to Entrepreneurship (Oncology Therapeutics Network and National Oncology Alliance) to a Fortune 20 Company (McKesson Corporation). Mike will also share his key lessons learned over this journey.
Speaker BioDr. Mike Cunningham is vice president and general manager of GPO & Information Services for McKesson Specialty Care Solutions, a business unit of McKesson Corporation.
In his current role, he is responsible for overseeing day-to-day business operations and leading long-term strategic planning for the company’s group purchasing organization (GPO), Onmark. He has a deep expertise in healthcare technology, with more than 25 years of experience in developing and implementing relationships with pharmaceutical companies and community-based practices. He is an expert in helping practices utilize technology to streamline clinical operations and inventory management to reduce clinic overhead. Dr. Cunningham co-founded the National Oncology Alliance (NOA) in 2002, an oncology GPO acquired by McKesson Specialty in 2005. Previously, Dr. Cunningham served for eight years as vice president of Oncology Therapeutics Network (OTN), a leading oncology and specialty services company acquired by McKesson in 2007. During his years with OTN, he helped grow the company into one of the largest specialty and oncology distributors in the nation.
Dr. Cunningham also spent 14 years at the University of California, San Francisco (UCSF), most recently as associate director of the Department of Pharmaceutical Services and director of Material Services. Dr. Cunningham continues to hold a position as associate clinical professor at the UCSF School of Pharmacy. He received his doctorate in pharmacy from the University of Southern California, performed two one-year residencies at UCSF and received a Master of Business Administration from the Walter A. Haas School of Business at the University of California, Berkeley.
Topic: “Reframing Health As More Than Health-care: Recognizing the importance of self-management and the role individuals have in designing their own well-being”Speaker: Rajiv Mehta, Zume Life, and Hugh Dubberly, Dubberly Design OfficeSchedule5:30-7:00 pm– Optional Dinner with BayCHI Friends (See dinner info at end of announcement)7:00-7:30 pm– Tea, Coffee, Socializing, Joining BayCHI7:30-9:30 pm–Program Location: PARC's George E. Pake Auditorium, 3333 Coyote Hill Road, Palo Alto, CADirectionsCost: FreeTopic DescriptionSignificantly improving the design of product and services for health requires a dramatic shift in thinking, from a paternalistic view of patient to a respectful view of person, and from a narrow goal of alleviating sickness to a holistic goal of supporting wellbeing. Noting that it is a wicked problem, we will expand the frame of health from traditional health-care to a resource for living. We will describe the varied challenges people face in executing their self-defined health self-management efforts and in conducting tiny self-experiments. Finally we will discuss the required change in design approach, challenging designers to focus on meta-design and to enable users to be the ultimate designers of their own health & wellness systems.Rajiv Mehta is a consultant on radical and disruptive innovation to technology and health companies, and founder and CEO of Zume Life, a start-up developing personal health management systems. Rajiv recently published A Billion Little ExperimentsHugh Dubberly is a partner in Dubberly Design Office, a consultancy that focuses on making hardware, software, and services easier to use through interaction design and information design. Hugh is also the editor for the On Modeling forum for Interactions.See details at http://www.baychi.org/program/#1
BayCHI organizes a dinner before each monthly meeting. This is a great opportunity to meet new people or to get together with your BayCHI friends. The evening's BayCHI speakers often attend. Held at a different restaurant near PARC every month, dinner begins at 5:30 p.m. and ends in time to make the talk at 7:30 p.m. This month, the dinner will be at:Sultana 1149 El Camino RealMenlo Park, California 94025(650) 322-4343 We'll meet at 5:30 p.m. sharp.RSVP by email by noon on the day of the meeting.Payment: Please plan to bring enough cash to cover your expected meal costs, plus 25% for tax and tip. This restaurant does not accept checks, so if for any reason you must use your checkbook, find a fellow diner with extra cash to cover you and write him or her a check. Credit cards are not an option. The magic words are "cash" and "please." Thanks for your cooperation! ***************************************************************MIT CNC Life Sciences Forum, Wednesday Night, March 10, 2010
Topic “Transparency in An Era of Health Reform”Speaker: Paul Levy, CEO of Beth Israel Deaconess Hospital The link for registration :http://tinyurl.com/MITCNCPaulLevyRegistrationDate and Time: Wedneday, March 10, 2010, 6:30 - 9:00 pm 6:30 PM --Networking including appetizers and beverages, 7:00 PM --Presentation 8:00 PM --Discussion and Networking Location: Berkeley City Club, 2315 Durant Avenue, Berkeley, CA 94704Cost:
General Standard Event Registration (Members of Affiliate Organizations need to enter discount code below)
$30.00
MITCNC Member Event Registration for current MITCNC Members
$20.00
Student Event Registration for Students
Topic DescriptionThere are often misconceptions as people talk about "transparency" in the health-care field. They say the main societal value is to provide information so patients can make decisions about which hospital to visit for a given diagnosis or treatment. As for hospitals, people believe the main strategic value of transparency is to create a competitive advantage vis-à-vis other hospitals in the same city or region. Both these impressions are misguided. Transparency's major societal and strategic imperative is to provide creative tension within hospitals so that they hold themselves accountable. This accountability is what will drive doctors, nurses, and administrators to seek constant improvements in the quality and safety of patient care.
Speaker BioPaul Levy, CEO of Beth Israel Deaconess Hospital and visionary in creating a transparent hospital will be speaking at the MITCNC HealthCare Forum on Mar 10th in Berkeley at the University Club. Paul is also a graduate of MIT and a great friend of MITCNC. He also has the very popular blog - http://runningahospital.blogspot.com/ Please join us for this very prestigious event! Refreshments will be served. Cash Bar.
CACO Workshop, Wednesday Afternoon, March 10, 2010
Topic: “ADME Sciences as Applied to Assessing Safety Testing (MIST)” Speaker: Scott Obach (Pfizer)
Date and Time:: Wednesday, March 10, 2010, 12:45 – 5:30 pm Location: Bay Area: Foster City Crowne PlazaEvent fee: $1 for unemployed; For others, details available upon online login.
Major Sponsor: (1)ABC Laboratories Vendor show vendors registered to date: (10)Absorption Systems; Applied Biosystems; Bruker Daltonics; Cerep, Inc.; MicroConstants, Inc.; Quotient Bioresearch; SRI International; Vitalea Science, Inc.; Waters Corp.; Xceleron Online registration and further details: http://www.caco-ca.orgRegistration deadline: 3/5/2010 (it will close sooner if the seating cap is reached)Additional Details: www.caco-ca.org
BayBio NEST Venture Spotlight Series, Thursday Morning, March 11, 2010
Topic: Heart MattersModerator:Jerry Iwata, Senior Vice President, Technology and Life Sciences Division, Comerica BankPanel Speakers:John Cornwell, Life Science AngelsAmr Schahieh, CEO, Apama MedicalRay Tabibiazar, Bay City CapitalLeslie Bottotoff, Onset VenturesLatham & Watkins, Menlo Park Campus, 140 Scott Dr., Menlo Park, CA 94025Early Bird Registration through March 9:$19.00 On-Site Registration, March 11:$29.00Register at http://www.baybio.org/institute/wt/page/VC_Spotight_3-2010
Topic Description
Heart disease is the leading cause of death worldwide, killing one person every 34 seconds in the US alone. In 2009, the estimated cost of cardiovascular disease in the United States was $475.3 billion according to the American Heart Association and the NHLBI. However, mortality rates have decreased due to improved prevention, diagnosis and treatment. This panel will discuss promising new areas of research and developing trends that are attracting funds.
The BayBioNEST Venture Spotlight Series is a unique forum that allows investors to speak directly to entrepreneurs in a reverse pitch format. Investors and experts have a platform to discuss their current interests, target markets, therapies and technologies, as well as the maturation level of investment targets. The Venture Spotlight Series is a breakfast panel discussion with time for Q&A and networking.
Pre-registered attendees will receive an immediate receipt/confirmation after submission.
Please print this receipt/confirmation and bring it with you to receive your conference credentials.
Photo ID (driver's license or passport) will be required at check-in. All sales are final - BayBio offers no refunds
Please mail your event-related questions to: [email protected] or you can contact us via phone: 650-871-7101 .
Panel Topic: Finding multiple faces of biomedical business and niche market with a perspective view from antibodies and peptidesModerator: Robert (Rong Ming) Lyu, Ph. D. Panelists : John C. Lin, M.D., Ph.D.Executive Director, Rinat, Pfizer Inc.; Anita Hong, Ph. D, President/CEO of AnaSpec and RonHwa Lin, Dr. rer. nat, President/CEO of AbGenomics International, Inc. Date/Time: 3/11/10 (Thursday) 6:30 pm– 9:00 pmLocation: Fenwick & West LLP, Silicon Valley Center , 801 California St. , Mt. View , CAFee: $5 for TAITA’s members, $10 for non-members.Contact: Robert (Rong Ming) Lyu, Phoenix Pharmaceuticals < [email protected]> More information on TAITA's Website (www.taita.us). Plenty of finger foods with soft drinks provided
Topic DiscussionBiomedical business has big opportunity due to a great demand from "ageing population" and the arriving of “health reform”. Can opportunity to gain knowledge for promoting your health also probably bring you a wealth? Business with antibody and peptide are good examples with two-digit numbers growth in the last decade and can be better for nextdecade. Especially, (1) Antibodies are good diagnostic tools and also becoming important new drugs for diseases. There are 22 therapeutic monoclonal antibodies on the market and several hundred of monoclonal antibody either in human clinical trials or under review by theUS FDA. The size of therapeutic antibody is projected to reach between $26 and $39 billion at 2010. (2) Advances in peptide synthesis, delivery, and formulation techniques, peptides applications has become more mature and broad. Since yr 2000 the number of therapeuticpeptides in clinical trial has doubled compared to the 1990s. Disregard the $3.5 billion anti-aging cosmedceuticals industry, the study goes on to note that 48 therapeutic peptides are now on the market worldwide, with 4 having generated global sales of more than $500 million each in 2007. Approximately 400 therapeutic peptides are nowmoving through the clinical trial process. What are the true drivers of new development? What are the challenges? What is the short- and long term market outlook? "Here are three highly accredited panelists will share their views for the coming niches. Speaker Bios
John C. Lin, M.D., Ph.D.completed M.D. from National Taiwan University in 1992, and received Ph.D. from Harvard University in 1998. After postdoctoral work at Genentech in 2001, he joined Rinat Neuroscience Corp., a biotech start-up developing novel antibody therapies for pain and Alzheimer's disease. He has joined Pfizer Inc. since 2006 when Pfizer acquired Rinat to expand their biotherapeutic portfolio. Dr. Lin is author of numerous publications and inventor of several US and international patents on neurology, metabolic disorders and autoimmunity. He served as grant reviewer for Michael J Fox Foundation for Parkinson's Research since 2006. He served as Board Director of TAITA-SV from 2007-2008. Anita Hong, Ph. D. received her Ph.D. in Physical Organic Chemistry from the University of Alberta in 1970. After worked in the Beckman Instruments, Inc. for eight years in Palo Alto , she worked for Applied Biosystems, Inc. (ABI) to establish the custom peptide synthesis group. In 1993, together with her husband, Dr. Frank Hong, she founded AnaSpec, Inc. in San Jose , CA. AnaSpec was initially conceived as simply a peptide synthesis service company; however, through expansion into complementary fields such as antibodies and technologies, it has since diversified into a multifaceted product/service company. In 2003, AnaSpec acquired HiLyte Biosciences, a developer and manufacturer of fluorescence detection reagents. At Oct. 2009, AnaSpec was acquired by Eurogentic. However, she will remain aboard the company in leading role in continuing to grow AnaSpec’s business. Rong Hwa Lin, Dr. rer. Nat after receiving a Dr. rer.nat (Immunology) degree from Tubingen University and Post-Doc. in Basel Institute for Immunology in Switzerland and Horward Hughes Medical Institute at Yale, he served as Professor and Director of GraduateInstitute of Immunology, Medical School , National Taiwan University . In 2000, he founded Abgenomics and began developing and marketing therapeutic monoclonal antibody at Taipei . Within only 10 years since, his company discovered more than 4 potential therapeutic candidates. The first drug candidate AbGn-168 has licensed to Boehringer Ingelheim in 2005 and start Phase I trial on March, 2009. To explore into other business arena, the company has reorganised and established its US headquarters, AbGenomics International Inc, in 2006. In this March 11, Dr. Lin will discuss his experience of establishing a company and the target-oriented monoclonal antibodies in various stages of pre-clinical and clinical studies. Let us explore the reasons why many bay area companies like Abgenix, PDL, Medarex and Rinat has been transformed by big pharma and prepare well for the changes in the coming decade.
Northern California Chapter, ACRP, Thursday, March 11, 2010
Topic: FDA's Bioresearch Monitoring ProgramsSpeaker: Stuart W. Russell, D.C., CSO/Investigator, FDA Pacific Region, SF DistrictDate and Time: Thursday March 11, 2010 6:00 – 9:00 PMLocation: Gilead Sciences, Inc., 300 Lakeside Drive, San Francisco Bay Conference Room, Foster City, CA 944046:00 – 7:00 PM: Registration sign-in, Networking, & Dinner Buffet7:00 – 7:30 PM: President's Welcome, Certificates of Appreciation, Door Prize, Announcements7:30 – 8:50 PM: Presentation 8:50 – 9:00 PM: Q&AEVENT REGISTRATION before Monday, 08 March 2010 11:59PM PST Register early to assure admission; at event IF space available (+$5.00 nonmember)REGISTER NOW – or click http://acrpnet.org/Northern CA Chapter
NCC ACRP member FreeACRP member $10Non-member $15CBRN & ACRP CONTACT HOURS have been applied for through ACRPPURCHASE NOW– or click http://acrpnet.org/Northern CA ChapterContact hours purchase not available at eventNCC ACRP & ACRP member $10Non –member $25Event registration and contact hour purchase information:NCC ACRP policy: No refunds or transfers. Membership not required for online registration/purchase. You will receive an email confirmation upon successful registration/purchase - please print and bring to the event.
Topic Description Your clinical site is about to be inspected by the FDA - what will happen and what will the inspector look for? The risk model used to select sites for inspection and data on recent BIMO (Bioresearch Monitoring) Program inspection findings in the US and internationally will be discussed. The incidence of scientific misconduct and fraud and specific detection techniques including statistical methods will be described and illustrated with case studies. Methods for detecting and preventing scientific misconduct and fraud as well as the FDA complaint handling system will also be reviewed. Bring your questions to this great opportunity to meet with an FDA inspector!
Speaker BioStuart W. Russell, D.C. is an FDA inspector specializing in Bioresearch Clinical Monitoring. He primarily inspects domestic sites but is also a member of the International Inspection Team. He additionally assures GLP and GMP practices are followed per the US CFRs for Pharmaceutical manufacturing facilities, Tissue and Reproductive facilities, and Blood and Plasma facilities. Dr. Russell earned his BS at Pepperdine University and his graduate Chiropractic degree at Los Angeles College of Chiropractic / S CA University of Health Sciences. Other areas of study include clinical orthopedics, biofeedback, nutrition, herbal, and homeopathy. He is retired from his chiropractic practice. Prior to joining the FDA, Dr. Russell was the National Manager/Formulator/Technical Writer for a Homeopathic, Herbal and Vitamin company, and has lectured nationwide in that capacity and authored multiple magazine articles and a book entitled, "Professional Complementary Combination Prescribing, A Desk Reference for the Herbal Practitioner" (not currently in publication).“Of all the work I do for the federal government, I find the most rewarding to be clinical research inspectional audits. This area of work ensures safe and effective drugs and devices come to market fulfilling a public need and I typically develop a relationship with the clinical investigator and staff to improve the research process.”
Target Audience: Clinical Research Professionals Sponsor Organizations Study Site Investigators & Coordinators Independent Consultants Students of Clinical Research Academic Medical/Clinical Researchers Service Providers/Vendors Institutional Review Boards Quality Assurance
UCSC Extension Intensive Clinical Trials Course, March 15-19, 2010
Course: Clinical Trial Essentials: An Intensive CourseExpert instructional team:
R. MICHAEL CROMPTON, J.D., M.P.H. is a regulatory affairs professional with more than 20 years of experience in the medical device industry. He is currently the vice president of Regulatory and Clinical Affairs and Quality at Micrus Endovascular Corp.
JERRY GEORGETTE, RN, MSN, CCRC, is a study nurse coordinator at the VA Palo Alto HCS and is past president of the Northern California Chapter of the Association of Clinical Research Professionals (ACRP).
MICHAEL HUSTON, M.B.A., B.S., is president of Huston Associates, LLC, and has more than 20 years of experience in the life science industry, from basic research to strategic drug development.
JACQUIE MARDELL, B.A., has a broad background in planning, implementation and analyzing clinical trials, and has lead teams in the preparation and execution of clinical development plans in many therapeutic areas.
JEAN MASONEK, RN, B.S.N., B.A., is the senior manager of drug safety at a Bay Area Biopharmaceutical company.
FRANCES A. MCKENNEY, M.S., is director of GCP compliance at Affymax. Ms. McKenney has more than 20 years of experience in the pharmaceutical/biotechnology industry, working for both sponsor/manufacturers and a CRO.
TAMMY MORTON-TAYLOR, M.S., has 18 years of research experience, with more than 13 years devoted to coordinating, monitoring and managing clinical trials. Her most recent clinical research focus has been in the medical device industry, where she has worked with devices for cardiology, women's health and endocrinology.
AUDREY ERBES, Ph.D., a marketing and business development consultant, Principal of Erbes & Associates and www.audreysnetwork.com, has more than 30 years of experience in the global biopharmaceutical industry, including project team role as business interface with clinical development
SUSANNE PROKSCHA, B.S., has worked in clinical data management and data management systems for more than 20 years and is the author of Practical Guide to Clinical Data Management.
EDWARD ROZHON, Ph.D., is a global studies manager in the Pharmaceutical Development Organization at Genentech/Roche. Dr. Rozhon has 22 years of pharmaceutical experience in nonclinical and clinical areas of drug discovery and development.
G. PETER SHABE, M.S., is a biostatistician and president of Advance Research Associates, Inc., a contract research organization (CRO) providing data-management and biostatistical services to the medical-device, biotech and pharmaceutical industries.
Dates and Time: March 15-19, 2010, 8:30 am – 5:00 pmLocation: 2505 Augustine Drive, Santa Clara, CACost: $1,675.00 (Fee includes all course materials, continental breakfasts, daily snacks and a networking lunch on the first day.)
For more information, please contact UCSC Extension's Applied and Natural Sciences Department at (408) 861-3860, or [email protected].
Course Description:Well-planned and well-executed clinical trials are the cornerstones of effective drug and medical device development. Offered in an accelerated format and taught by leaders in the biopharmaceutical industry, this course provides a unique opportunity for professionals from all disciplines to learn about the many facets of clinical trials--the complex process that ensures the safety and effectiveness of medical products. Participants leave the program with an appreciation of the drug and device development process; good clinical practice (GCP) and other regulations (ICH and FDA) that guide the conduct of trials and protect human volunteers; clinical trial phases and design strategies; the importance of informed consent and the role of the IRB; investigator selection and responsibilities; study site management and trial monitoring; statistical data analysis; and regulatory responsibilities and the role of the FDA. This course benefits anyone working in the biopharmaceutical and medical device industries and the biomedical community who is interfacing with or conducting clinical research, including new clinical research associates and study coordinators; medical directors, physicians, nurses, pharmacists, and other health professionals; biomedical scientists; statisticians and database administrators; and business professionals. A team of clinical research experts, including many instructors from the Clinical Trials Design and Management Certificate Program, will present the following topics:
Overview of the Drug and Medical Device Development Processes Clinical Trial Design Applied Statistics in Clinical Trials for the Non-Statistician Regulation of Clinical Research (including GCP and ICH) Roles and Responsibilities of Key Clinical Research Players, including the
Investigator, the Sponsor, the Clinical Study Site and the FDA Institutional Review Board (IRB) Perspectives Monitoring Clinical Trials Clinical Data Management Clinical QA, Auditing and Compliance Safety Reporting The Business of Clinical Research
FountainBlue Life Science Forum, Monday Evening, March 15, 2010
Topic: International Challenges and Opportunities for Life Science CompaniesFacilitator from Morrison Foerster to be confirmed Panelist William Goure, President and CEO, Acumen PharmaceuticalsPanelist Taylor Kilfoil, President and CEO, InClin, Inc.Panelist Evgeny Zaytsev, General Partner, Helix Ventures
Presenting Entrepreneurs to be confirmedDate & Time: Monday, March 15 from 5:30 - 7:30 p.m. Location: Morrison Foerster, 755 Page Mill Road, Palo AltoCost: $21 members, $32 partners, $42 general
On-Site Registration is $42 for members, $52 for nonmembers, or $124 for FountainBlue Ongoing membership and admission
Registration: Please pre-register by noon on 3/12 using the PayPal link at http://www.svlifescience.com.
Audience: Life Science entrepreneurs, intrapreneurs and investors, no service providers please
Topic DescriptionResilient, resourceful, life science entrepreneurs are advancing their businesses, and developing international programs and relationships to better advance their technology, provide clinical research, and serve their markets. For this panel, life science entrepreneurs, intrapreneurs and investors on what's working and what's not in different international markets.
Panelists' BiosFacilitator John Bashkin, Vice President, Strategic Business DevelopmentDr. John Bashkin has 18 years of experience in technology, product, and business development for life sciences and medical devices. He has held senior business development positions at SRI International and, most recently, at Artificial Muscle, Inc.
While at SRI for seven years, Dr. Bashkin headed up business development efforts for life science and medical device technologies from across the institute as well as led his own NIH-funded research programs and served on the IP Committee for the Institute. He led contract and out-licensing negotiations for many technology and product development programs.
At Artificial Muscle, he was responsible for all corporate contract matters as well as business development for the medical industry. Prior to joining SRI, Dr. Bashkin was a senior researcher at Molecular Dynamics and Amersham, where he led the development of the first high-throughput DNA sequencing system.
He received his B.S. in Chemistry and Physics from the University of Arizona, his Ph.D. in Chemistry from Indiana University, and held post-doc positions at the University of Rochester and Johns Hopkins University. In 2000, he received his MBA from Santa Clara University.
Dr. Bashkin is a co-inventor on five issued U.S. patents and co-author on more than 20 publications.
Panelist Dr. William Goure, President and CEO, Acumen Pharmaceuticals Since May 2008, Dr. Goure has been President and CEO for Acumen Pharmaceuticals. Dr. Goure has over 20 years of domestic and international experience in the discovery, development, registration, commercial development, and commercialization of chemical and biotechnology products.
Prior to joining Acumen, Dr. Goure was Vice-President for Commercial Development for Mendel Biotechnology, a bay area company dedicated to creating value through the discovery, development and commercialization of knowledge about plant gene expression. At Mendel, Dr. Goure negotiated numerous technology collaboration and partnership agreements that generated over $29 million dollars of near term revenues.
Prior to joining Mendel, Dr. Goure worked for Monsanto Company for 17 years where he developed and commercialized Roundup Ready® soybeans, canola, and cotton. Dr. Goure was a member of the team that established Monsanto's quality traits program that led to the Renessen joint (partnership) with Cargill, and was responsible for establishing commercial launch teams in Eastern Europe, South Africa, and Southern Latin America.
Dr. Goure has a B.S. degree in Chemistry from Fort Lewis College, Durango Colorado, and a Ph.D. degree in organic chemistry from Iowa State University. Prior to joining Monsanto, Dr. Goure was a Post-Doctoral Fellow at Colorado State University.
Panelist Taylor Kilfoil, President, CEO and Co-Founder, Inclin, Inc.
11 4/7/2023
Taylor Kilfoil is the President, CEO and Co-Founder of Inclin, which provides a range of clinical, regulatory, and quality assurance services to pharmaceutical, biotechnology, and medical device companies. Taylor earned a Bachelor of Science from St. John's University.
Panelist Dr. Evgeny Zaytsev, General Partner, Helix VenturesEvgeny Zaytsev co-founded Helix Ventures in 2008 and brings eight years of venture capital and nine years of operations and research experience to the firm. Since 2001 together with Graham Crooke he managed the life sciences portfolio in two venture capital partnerships at Asset Management Company, one of the oldest venture capital firms in Silicon Valley. He was one of the key executives of the Medico-Ecological Institute, a research institute established in Russia in 1993 to study the health and environmental effects of the Soviet Union's nuclear testing program. An expert in physiology and radiation biology, he was chief scientific officer from 1994 to 2000 and during his tenure the institute became an internationally recognized research center. He is the author or co-author of 45 scientific and business publications, including six books on radiation and cancer epidemiology. From 1991 to 2000, he was also an assistant professor in physiology at the Altai State Medical University in Barnaul, Siberia.He received his M.D. (cum laude) in 1991 and his Ph.D. in physiology in 1993, both from the Altai State Medical University. He earned his M.B.A. from the Stanford Graduate School of Business in 2002. He is currently a director of several private life sciences companies. He is an Advisory Board member and past president of the American Business Association of Russian Professionals ("AmBAR").
Topic: “Medical Device Clinical Research around the World” Speaker: Dr. Sujith Shetty, Clinical Research Manager, Micrus Endovascular Corp Date and Time: Tuesday, March 16, 2010, 8:30 – 10:30 amLocation: Sunnyvale City Council Chambers, 456 W. Olive, Sunnyvale, CA (across the street from Sunnyvale Public Library)Cost: FreeParking: On street and in NOVA and library parking lots across the street.
Topic DescriptionDr. Shetty will be speaking about the challenges and opportunities of conducting clinical research in and outside the U.S. He will share insights about the need for clinical research and evidence based medicine and how it impacts industry. He will also discuss the challenges seen in working in various countries around the world. Clinical Research and its impact on a biospace company can be significant in terms of effectively presenting a novel device to the marketplace. Good Clinical results can significantly facilitate the issuance of regulatory approvals and it is also an effective tool to introduce the new product to physicians.
Speaker BioDr. Sujith Shetty is currently the Clinical Research Manager at Micrus Endovascular Corp where he is engaged in pre- and post-approval clinical research of intravascular neurologic devices. He was the Manager of Scientific Affairs at Pulmonx, and Senior Research Associate at Asthmatx, and Clinical Research Fellow at USC Keck School of
12 4/7/2023
Medicine. Dr. Shetty received his medical training at the Kempegowda Institute of Medical Science in Bangalore, India.
NorCal BioPharmaPM, Friday Morning, March 19, 2010
The NorCal BioPharmaPM holds monthly breakfast meetings. These meetings are open to anyone who is interested in project management and works for the Pharma, Biotech, Medical Devices or Life Sciences industries Topic: “How to Become a Great Project Manager “Speaker: Charles Follett, partner of the Stratam Group Date and Time: Friday, March 19, 2010, 8:00am – 10:00am Location: Novartis Pharmaceuticals Corporation, 150 Industrial Road, San Carlos, CA 94070Phone: (650) 622-1500Cost: Free Register at: BioPharmaPM.com, to confirm your reservation. Event Contact Info: NorCal BioPharmaPM Vice Chair , Doug Tambling ******************************************************************* Palo Alto AWIS, Monday Evening, March 22, 2010
Topic: Stem Cells and Women's HealthSpeaker: Dr. Reijo PeraDate and Time: Monday, March 22nd, 2010Schedule7:00-7:30 pm Networking and light supper7:30-7:45 pm Announcements7:45-8:45 pm Program8:45-9:00 pm DiscussionLocation: PARC Auditorium, 3333 Coyote Hill Road, Palo AltoRSVP: online http://www.acteva.com/go/pa-awis
Topic DescriptionDr. Rejio Pera will discuss her research on Stem cells andreproduction, Women’s somatic health and Women in Cancer.
In recent years, much emphasis has been placed on realizing the promise of stem cells in medicine. Yet, little focus has been placed on issues related to women’shealth. We seek to improve women’s health through stem cells.
Stem cells and reproductionIn the USA, reproductive failure carries a cost burden that exceeds $6 billion annually.Yet, research on reproductive failure, especially on the earliest stages of humanreproduction, has been excluded from federal funding. Our group explored the use ofmodern developmental genetic and biophysical means to develop novel diagnosticsand interventions based on scientific evidence. The use of assisted reproductivetechniques to alleviate reproductive failure results in the annual culture of more than amillion embryos. Unfortunately, the vast majority of cases fail to develop properly forunknown reasons. We have sought to remedy the current state, with studies that willresult in the optimization of embryo culture and diagnosis of germ line and embryodevelopmental competence and subsequent fetal and neonatal consequences.
Cardiovascular disease has been the leading cause of death in women for decades;diabetes and autoimmune diseases disproportionately afflict women and with theextension of women’s lifespan, degenerative disorders such as urinary incontinence.Given these facts, a concerted effort to capitalize on the potential of stem cells insomatic health of women is merited.
Women and CancerSeveral cancers are most frequent or exclusive to women including breast cancer andovarian cancer. Promising potential therapies include immunologically-basedtherapies and therapies aimed at targeting cancer stem cell populations. Efforts tofocus cancer stem cell efforts on women’s cancer will be discussed.We have unprecedented opportunity to explore the unique biology of humandevelopment, including that of women, with the advances in stem cell biology
Welcome!! You don’t need to be a member to attend.All scientists, students, and their friends are welcome. Men too!Members and students pay $5 and non-members pay $10
**********************************************************************Bio2Device Group, Tuesday Morning, March 23, 2010
Topic: “Starting Out Right: The Key Legal Considerations in Setting up a Life Sciences Company” Speaker: Deborah A. Marshall, Partner, Sidley Austin, LLPDate and Time: Tuesday, March 23, 2010, 8:30 – 10:30 amLocation: Sunnyvale City Council Chambers, 456 W. Olive, Sunnyvale, CA (across the street from Sunnyvale Public Library)Cost: FreeParking: On street and in NOVA and library parking lots across the street.
Topic Description
Silicon Valley is frequently described as a unique ecosystem of entrepreneurs, research institutions, investors and advisors who have developed a common language and way of doing business that enables innovation and growth. This common language is reflected in the key agreements that every company must put into place in order to effectively create, develop, protect and commercialize its technology. Join us for a lively discussion of the legal aspects of the startup process.
Speaker BioDeborah A. Marshall, a partner with the Sidley firm, concentrates her practice on strategic business counseling for emerging growth companies and investors at all stages of development, from start-up entrepreneurs to publicly traded entities and technology-based, multinational corporations. Ms. Marshall has advised issuers, investors and investment banking firms in the internet, software, electronics, clean technology, media, entertainment, biopharmaceutical, genomics, medical device and diagnostics sectors. She has significant experience in venture capital financing, mergers and acquisitions, public offerings, private equity and strategic partnerships.
Ms. Marshall is a frequent speaker on issues related to venture capital, emerging growth companies, life sciences, public securities and entrepreneurship. She has been a guest lecturer on entrepreneurship at the University of California Berkeley Haas School of
14 4/7/2023
Business, as well as a member of the faculty of the Haas Business School’s Global Bio-Executive Program.
Ms. Marshall’s work as a corporate lawyer is highlighted in the 2007 Corporate and Finance version of The Legal 500 United States edition.
BioScience Forum, Wednesday Evening, March 24, 2009
Topic: "Personalized Medicine: Yesterday, Today and Tomorrow. How Genomic Information has, is and will Change Healthcare" Speaker: Steve Rosenberg, Ph.D., Chief Scientific Officer, CardioDxDate and Time: Wednesday, March 23, 2010; 6:00pm - 9:00pm6:00 PM - networking 7:00 PM - dinner 8:00 PM - presentationLocation: The Clarion Hotel, 401 East Millbrae Avenue, MillbraeFull info and Registration at:http://biosf.org/
Typical Cost: $50 before 11:55 PM, Monday, March 22nd$60 on-site$35 full-time students pre-registration$45 full-time students on-site Acteva fees of $3 are added to the above prices Check website for latest informationCash or check accepted on the day of the eventParking is $2 Or you can pay with a check made out to "BioScience Forum" and sent to: BioScience Forum, 1442A Walnut Street, #308, Berkeley, CA 94709-1405 Please do not mail checks later than Thursday, March 18thIf paying with check, do not complete registration with Cvent
Topic DescriptionThe ability to decipher genomes started with viruses and bacteria and rapidly moved to eukaryotes and finally to mammals, especially Homo sapiens. The speed at which this technology has progressed is mind-boggling, from Maxam-Gilbert sequencing in the 70s to single molecule sequencing today. But how has this tsunami of information benefited human healthcare? Steve will discuss early examples from virology, cite current examples from oncology and cardiovascular diseases, and speculate on what the future may hold. BiographySteve has been the Chief Scientific Officer at CardioDx, a molecular diagnostics company, focused on the application of genomic information to cardiovascular diseases, since 2006, and led the team which launched Corus CAD™, a blood based gene expression test for the assessment of coronary artery disease, in 2009. Prior to that he spent three years at XDx, leading the team which developed Allomap™ gene expression testing for detection of rejection in heart transplant recipients. From 1981 to 2001 Steve occupied positions of increasing responsibility at Chiron Corporation, where he was named one of three Chiron Fellows in the company. He completed his PhD and post-doctoral work in biochemistry at UC Berkeley.
Topic: “Establishing and Successfully Managing Strategic Alliances”Panel Moderator: Mike Brasseur, Vice President, Business Solutions, M Squared Consulting, Inc. - Life SciencesPanel Speakers: Patrick Bigot, Senior Director, Head of Alliance Management, Genentech, Inc. Patrice Bruneman, Director, Strategic Alliances, Medivation Monique Nicoll , Sr. Director, Research & Discovery Alliance Management, Exelixis, Inc.Venkat Ramanan, Director, International Access Operations, Gilead Sciences, Inc.Date and Time: Thursday March 25, 2010, 8:00am – 10:00amLocation: Wells Fargo Insurance Services Inc., 305 Walnut Street, Redwood City, CA 94063Register at: http://www.baybio.org/wt/page/managing_strategic_alliancesEvent Contact Info: [email protected]: Through March 23: $10 BayBio and ASAP members, $20 non members; On-site registration March 25: $20 BayBio and ASAP members, $40 non members
Topic Description The current economic climate, and market pressures are forcing a change in strategy for both established and emerging life sciences companies. The IPO market is gone. The VC funding is dry. Companies, seeking to deliver new treatments and cures, are forming alliances with larger organizations at a faster pace. Some are even saying that we are witnessing a fundamental change, where success will depend on a company's capacity to manage multiple relationships as part of a larger collaborative network. To be successful, companies will need to effectively develop and manage alliances, they must also learn how to remain relevant to their partners and be flexible enough to evolve with changes in the partner's strategy. Join us for a panel of expert Alliance executives to learn how to become "alliance capable" and thrive through collaborations in the new environment.
Location: Orrick, Herrington & Sutcliffe LLP, Silicon Valley Office, 1100 Marsh Road, Menlo Park, CA 94025-1015*Pre-registration closes on March 23rd at noon!*• Regular Price: $60• Partners' Network: $50• BioCenter Members: Free (please RSVP to Aurélie)• On-site Registration: add $10 to the above This event is typically sold out, so early pre-registration is recommended to avoid disappointment on the day!Register at http://www.acteva.com/booking.cfm?bevaid=196787
Topic DescriptionEffectively raising capital is crucial for any company. Sufficient capital helps ensuring R&D, Due Diligence, Legal and Accounting services, Marketing, and improves hiring potential. In this session, a panel of VCs and CEOs will deliver the tips and tricks to realizing a successful financing process. Questions that will be raised include:» What are the steps to prepare for a financing round?» What are the strategies for attracting, securing and structuring financing deals?» Is there a valuation best practice for an emerging company in this complex environment?» When to start your financing round, and when not to? Our Panel discussions are candid, interactive and informal. We want you to walk away with the real story behind how things work so you can make it happen yourself. This Panel will be followed by a Networking Reception.
Topic: “Careers for Scientists in the Legal Professions”A panel discussion featuring:
Madhuri “Mani” Roy, PhD, Scientific Advisor and Patent Agent, Wilson Sonsini Goodrich and RosatiKathleen McCowin, JD, MS, Licensing Officer, Office of Technology Licensing,University of California, BerkeleyCarol Mimura, PhD, Assistant Vice Chancellor for Intellectual Property & Industry Research Alliances,University of California, Berkeley
Date and Time: Thu, March 25, 6:30pm – 8:30pmLocation: Novartis, Building X-310, 5300 Hollis Street (map)Description
*************************************************
San Jose State University Biomedical Engineering Society, Tuesday, March 30, 2010
Event: Bay Area Biomedical Device Conference 2010
Speakers: Julian Nikolchev, Founder & CEO, Pivot, Inc. Rob Abrams, Operating Partner, Sanderling Ventures Tom Bauer, M.D., Ph.D., The Cleveland Clinic Foundation Larry Eiselstein, Ph.D, P.E., Exponent, Inc. Raj Makkar, M.D., Ph.D., Cedars’ Sinai Medical Center
Jeffrey Lotz, M.D., Ph.D., Professor, University of California, San FranciscoDate and Time: Tuesday, March 30, 2010, 8:00 am – 5:00 pmLocation: Engineering Auditorium at SJSUFor details and on-line registration, go to:http://www.engr.sjsu.edu/bmes/2010Conference.htmlCost:
$195 Early Registration $245 Late Registration (After 3/17/2009) $275 Walk in registration $40 SJSU Students $75 Non-SJSU Students
Event DescriptionThe Organizing Committee has identified and invited a set of outstandingspeakers who will address several areas that are critical to the biomedicaldevice industry. There will be presentations on interventional cardiology,device explants, corrosion of implants, intervertebral disc degeneration andregeneration, appropriate selection of animal models for clinical trials,regulatory affairs and entrepreneurship pertaining to medical devices. Thisevent will not only cover technologically significant advances in the field,but will also serve as a networking opportunity.
Free UCSC Extension Bioscience Program, Tuesday Evening, March 30, 2010
Topic: Bioscience Program Information and Q&A Session
Instructor: Michelle Ragozzino, Ph.D., Program DirectorDate and Time: Tuesday, March 30, 2010, 6:30 – 8:00 pmLocation: 2505 Augustine Drive, Santa Clara, CACost: No fee but enrollment requiredRegister at www.ucsc-extension.edu
Course Description:
This free evening event is an informal discussion geared towards new or returning students interested in one or more of the Bioscience certificate programs. Led by the director of the Bioscience programs, the event begins with a short overview of the five Bioscience certificates, followed by an open-floor segment for audience questions.
FountainBlue, Friday Morning, April 2, 2010Topic:” FountainBlue's Funding Road Trip: Perfecting Your Pitch to Investors”Speaker: Bill Joos, principal of "Go To Market ConsultingDate and Time: Friday, April 2, 8:30 a.m. - 1:00 p.m.8:30 Registration and Networking, in the Cooley Café 9:00 Bill Joos: Perfecting Your Pitch to Investors, in the Cooley Café 10:30 Morning Break 10:45 Pitch Practice Sessions - 15 mins a team1:00 Optional Pitch Debrief Meeting 1:30 Adjourn. Please note that we have the room until 1:45 p.m. and we welcome you to stay to network with fellow entrepreneurs.Location: Cooley Godward Kronish LLP, 3175 Hanover, Palo AltoAudience: Early-Stage, Funding-Bound Clean Energy, High Tech and Life Science
18 4/7/2023
Entrepreneurs and Intrapreneurs, who have attended our October and/or our November workshops
Cost for 1 or 2 Entrepreneurs: $83 for FountainBlue members, $93 for Partners, $103 GeneralOn-Site for members is $103 and $124 and for non-members.
Registration: Please pre-register by noon on 3/31 using the PayPal link at http://www.fountainblue.biz/fundingroadtrip.html.
Topic DescriptionFountainBlue cordially invites high tech, life science and clean energy entrepreneurs to the second funding preparation workshop entitled 'Perfecting Your Pitch to Investors'. This hands-on workshop, which follows the first workshop entitled 'Your Company's Value Proposition', will take entrepreneurs through the process of creating and delivering a compelling elevator pitch, a one-page executive summary and a 13-15 slide company overview presentation. Attendance at one of the two workshops in the series is a pre-requisite to attending our third and final workshop in the series, 'Your Meeting with Investors', which features feedback from active investors. For this workshop, working in partnership with fellow entrepreneurs in similar, non-competing spaces, participating entrepreneurs will have the opportunity to learn best practices and immediately apply these learnings to their own companies. Whether you are a serial entrepreneur, or someone who may be considering a future opportunity, you are sure to benefit from the information presented, the connections made and the peer-to-peer knowledge shared.
Speaker BioBill Joos is the principal of "Go To Market Consulting", based in Palo Alto, CA. He works with early stage startups, venture capital firms and their portfolio clients. Most recently he spent 6 years as the VP of Entrepreneur Development at Garage Technology Ventures, an early stage venture capital firm that he co-founded along with Guy Kawasaki. His reputation at Garage was that he provided their clients with effective, hands-on, action-oriented strategic and tactical mentoring and coaching. Bill has worked with literally hundreds of early-to-mid stage startups and helped them polish and clarify their messages and refine their fund-raising and customer presentations; but his contributions to them extended well beyond being a "Pitch Doctor". He has mentored and coached them in go to market strategies, revenue and pricing optimization, business alliances, business development, partnerships, and marketing. Over 15,000 entrepreneurs worldwide have attended conferences where Bill has been a featured keynote speaker on various entrepreneurial topics. He has held sales and marketing positions with a variety of companies, including IBM and as a VP of the software division of Apple Computer.
Topic: Self-guided SurgerySpeaker: John Black, Avinger Date and Time: Tuesday, March 16, 2010, 8:30 – 10:30 amLocation: Sunnyvale City Council Chambers, 456 W. Olive, Sunnyvale, CA (across the street from Sunnyvale Public Library)Cost: Free
Topic: “A Serial Entrepreneur's Journey- How a Physicist became a Leading Device Innovator” Speaker: Hira Thapliyal, Ph.D., President and CEO, VytronUS, Inc.Date and Time: 4/13/2010, 6:00 pm Location: TIPS, 1000 Elwell Ct., Suite 150, Palo Alto, CA Cost: $6 - Students/In-transition - Members only $11 - Early-bird Registration - Members only $20 - Late Registration and Non-Members $25 - Walk-ins Register online at www.bio2devicegroup.org
Topic DescriptionHira Thapliyal will discuss his journey from a physicist to a leading serial entrepreneur in Silicon Valley/USA. He will discuss the highs and lows, and some lessons he has learned along the way. Along his successful career path you will see familiar companies that he has lead and/or founded such as DVI, CVIS, Arthrocare, Tescient, MicroBionics, and VytronUS.
Speaker BioDr. Hira Thapliyal, Ph.D., got started in the medical device industry while developing a cauterizing, glass scalpel. A cardiovascular industry veteran, who played a critical role in the founding of companies such as atherectomy pioneer DVI (Devices for Vascular Intervention Inc.), and intravascular ultrasound leader CVIS (Cardiovascular Imaging Systems, now part of Boston Scientific Corp.). Three years later he became CEO of MicroBionics, Inc. Thapliyal then founded a new company in April 1993 called ArthroCare Corporation, which used coblation technology to facilitate arthroscopic joint surgery. Dr. Thapliyal served as the company's initial president and chief executive officer. Hira then co-founded and was CEO of Tescient, Inc. Hira is currently the President & CEO of VytronUS, Inc. VytronUS is developing products in cardiovascular field. Hira is currently a member of the Board of Directors for Apsara Medical, Inc., Intact Medical, Inc., and PAVAD Medical, Inc. He is also the Special Partner of MedVenture Associates IV. Dr. Thapliyal is also an Advisory Board Member to the Department of BioEngineering at University of California, Berkeley and Materials Science and Engineering at Cornell University.Dr. Hira Thapliyal earned his B.S. in electrical engineering from Washington State University, followed by an M.S. in electrical engineering from the University of Idaho and a Ph.D. in materials science and engineering from Cornell University.
**********************************************************************Bioscience Business and Marketing Essentials, Thursday and Friday, April 15-16, 2010
2-Day Intensive Course: Bioscience Business and Marketing Essentials, Thursday and Friday, April 15-16, 2010 with 2 months to complete projectLead Instructor: Audrey S. Erbes, Ph.D., Principal, Erbes & Associates and www.audreysnetwork.comExpert Guest Speakers: Donald Holsten, Pharm. D., Regulatory Consultant and Educator
Bev Hudson, MBA, General Manager, Clinical Research Services, MedPoint Communications, Inc Julie Tompkins, MBA, Sr. Vice President, Timely Data Resources (TDR)Please see www.ucsc-extension.edu/biobusiness for complete biographiesDate & Time: April 15-15, 2010, Thursday and Friday, 8:30am-5pmLocation: UCSC Extension in Silicon Valley, 2505 Augustine Drive, Santa Clara, CA 95053Fee: $750; $675 through April 1
Topic DescriptionThe bioscience industry is like no other. Lengthy timelines and unique financial, legal, regulatory, social and political challenges impose constraints that impact every aspect of the business. This course helps participants gain: a practical understanding of the bioscience industry landscape, key business drivers and challenges; insight into the critical roles that business and marketing disciplines play at all stages of a bioscience company's development; and hands-on experience implementing important bioscience business processes that are essential to success within the industry. Two days of intensive classroom are followed by 2 months to complete individual project with guidance of instruction and access to research resources. For more information: See www.ucsc-extension.edu/biobusiness.
Instructor BioAudrey Erbes, Ph.D., Principal of Erbes & Associates and www.audreysnetwork.com, is a marketing consultant with more than 30 years of managerial experience in marketing and business development in the biotech and pharmaceutical industries. She was Executive Vice President and cofounder of Kowa Research Institute, a biopharmaceutical licensing and investment subsidiary of Kowa Company Ltd., Japan and before that held management positions at Syntex Corp. in market research, product management, strategic marketing and planning, and business development in the U.S. and abroad.
BayBio NEST Venture Spotlight, Thursday Morning, April 15, 2010
Topic: “A Tailor Made Approach: Personalized Medicine”Panel Moderator: Jeff Peterson, CEO, Target DiscoveryPanel Speakers: Bill Gerber, Bay City CapitalDate and Time: April 15th, 2010, 8:00 – 10:00 amLocation: Latham & Watkins, Menlo Park Campus, 140 Scott Dr., Menlo Park, CA 94025Cost: Early Bird Registration through March 13th:$19.00;On-Site Registration, March 15th:$29.00Register at http://www.acteva.com/booking.cfm?bevaid=195773
(If you are an employee of a Sponsor company, please contactProgram Manager, Jessica Knowles to obtain your complimentary registration.)
Topic DescriptionThe crisis of health care economics is now frighteningly familiar to us all, driven by advancing technology often coupled with increasing cost. Personalized Medicine is our greatest hope for remediation of this rising economic tsunami. Decades of advances in molecular biology are now delivering important new diagnostics for Personalized Medicine (PMDx) to determine the patient's response, resistance or toxicity risk before or during treatment, in order to optimize the selection of medical treatments from amongst the alternative options. Patients benefit enormously by not wasting valuable months of
treatment time and not undergoing the side effects and physical insult of ineffective or toxic treatments like chemotherapy in cancer.
The BayBioNEST Venture Spotlight Series is a unique forum that allows investors to speak directly to entrepreneurs in a reverse pitch format. Investors and experts have a platform to discuss their current interests, target markets, therapies and technologies, as well as the maturation level of investment targets. The Venture Spotlight Series is a breakfast panel discussion with time for Q&A and networking.
Topic: tbaSpeaker: David DeNolaDate and Time: Tuesday, April 20, 2010, 8:30 – 10:30 amLocation: Sunnyvale City Council Chambers, 456 W. Olive, Sunnyvale, CA (across the street from Sunnyvale Public Library)Cost: FreeParking: On street and in NOVA and library parking lots across the street.
BioScience Forum, Wednesday Evening, April 21, 2010
Topic: TBA Speaker: Jean Deleage, Ph.D., Founding Partner and Managing Director, Alta PartnersDate and Time: April 21st, 2010
Date and Time: Wednesday, April 21, 2010; 6:00pm - 9:00pm6:00 PM - networking 7:00 PM - dinner 8:00 PM - presentationLocation: The Clarion Hotel, 401 East Millbrae Avenue, MillbraeFull info and Registration at:http://biosf.org/
Typical Cost: $50 before 11:55 PM, Monday, April 19th$60 on-site$35 full-time students pre-registration$45 full-time students on-site Acteva fees of $3 are added to the above prices Check website for latest informationCash or check accepted on the day of the eventParking is $2 Or you can pay with a check made out to "BioScience Forum" and sent to: BioScience Forum, 1442A Walnut Street, #308, Berkeley, CA 94709-1405 Please do not mail checks later than Thursday, April 15thIf paying with check, do not complete registration with Cvent**********************************************************************
San Jose Biocenter, Thursday All-Day, April 22, 2010
9:30 AM - 10:30 AM Presentation & Q&A 10:40 AM - 11:30 AM BioCenter Tour11:30 AM - 12:30 PM Lunch & Networking12:30 PM - 5:00 PM One-on-one Meetings One-on-one Meeting Application & Costs• Application fee: FREE• Registration for one company representative: o $175 Regular o $150 Partners’ Network • Registration for two company representatives: o $250 Regular o $215 Partners’ Network• Registration for three company representatives: o $300 Regular o $255 Partners’ Network• Registration for four company representatives and above: o add $40 [or $30 for Partners’ Network] per attendee• BioCenter Residents and Affiliates: Free
Presentation & Q&A Costs**• Regular Price: $40• Partners' Network: $30• BioCenter Members: Free (please RSVP to Aurélie)**Includes: Presentation & Q&A session ONLY. Seating is limited for this event, so early pre-registration is recommended to avoid disappointment! Additionally, there will be no on-site registrations.
Topic DescriptionEmerging companies find it increasingly difficult to reach the right person when seeking funding and/or partners. Through the “Meet with…” Series, we provide emerging companies with greater access to partnering and/or financing opportunities. In this session, Directors from Amgen will talk to potential licensees to first explain what they are looking for in a company. After the presentation, each pre-approved attendee* will be granted a private meeting with a Director from Amgen.
*Registrations to one-on-one meetings are subject to approval of application. To apply, please send your Executive Summary by April 4, 2010 to Aurélie at [email protected]. The Review Board, composed of the BioCenter management team, sponsors, partners and mentors, will then meet to consider your application. You will be notified on April 8, 2010 if your application is accepted or rejected. Registration must be completed upon approval to secure your meeting slot.
***************************************************************BayBio Institute NEST,
Topic: Technology Showcase at SRIDate and Time: April 29th, 2010, 5:30-7:30pmLocation: SRI International, 333 Ravenswood Avenue, Menlo Park CA 94025Cost: Early Bird Registration through April 28th - $29; On-Site Registration, April 29th - $39Register at http://www.acteva.com/booking.cfm?bevaid=196082
Topic DescriptionBayBioNEST invites you to join us for the first of the 2010 Technology Showcases at SRI International. The NEST Tech Showcase allows the life sciences community to get a sneak peak at the science within often before it is published or patented and is also a great opportunity for the industry community to network with scientists, entrepreneurs and with each other.SRI International is an independent nonprofit research /development organization in existence over 60 years, whose discoveries, patents, and inventions have touched people's lives around the world!SRI's Biosciences Division provides complete discovery and preclinical development capabilities to take drugs and biologics from Idea to IND®. Our integrated program offers the scientific, technical, and regulatory expertise needed to expedite the process. We provide target identification, lead discovery/optimization, vaccine development, neuropharmacology research in sleep and pain, microbiology, efficacy models, comprehensive toxicology, PK/ADME, formulation, analytical chemistry, cGMP manufacturing, QA, IND preparation and government grant teaming services. In its CRO business, SRI has helped its clients, partners, and the Government advance well over 100 drugs into patient testing. SRI is also working to create the next generation of technologies in areas such as diagnostics, drug delivery, medical devices, and systems biology.*********************************************************************
